Friday, April 05, 2019 7:47:43 PM
SALT LAKE CITY, April 3, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court ("Delaware") alleging that Clarus's JATENZO(R) product infringes six of Lipocine's U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and 6,923,988.
"We have invested significant resources in developing innovations that have led to our importantly held strong intellectual property rights. We will defend those rights when infringed upon," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine.
About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs: TLANDO, LPCN 1144, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of NASH. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials, the timing of completion of clinical trials, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-seeks-injunction-against-the-marketing-of-clarus-therapeutics-jatenzo-for-testosterone-replacement-therapy-300823892.html
SOURCE Lipocine Inc.
/CONTACT: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383, mb@lipocine.com, Investors: Hans Vitzthum, Phone: (617) 535-7743, hans@lifesciadvisors.com
/Web site: http://www.lipocine.com
> Dow Jones Newswires
April 03, 2019 09:34 ET (13:34 GMT)
Recent LPCN News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 01:35:10 PM
- Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® • PR Newswire (US) • 09/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 03:23:16 PM
- Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 • PR Newswire (US) • 08/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 10:20:27 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 10:19:03 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/07/2024 08:05:52 PM
- Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study • PR Newswire (US) • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:00:30 PM
- Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 • PR Newswire (US) • 06/10/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:43:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:41:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:39:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:32:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 09:09:23 PM
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 • PR Newswire (US) • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:06:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 10:03:08 AM
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 • PR Newswire (US) • 05/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 10:15:30 AM
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 • PR Newswire (US) • 05/01/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM